

## CEFX/EFX Ultra SuperStim Pools: Superior positive controls for T-cell assays with broad MHC-allele and antigen coverage

M. Eckey<sup>1</sup>, U. Reimer<sup>1</sup> & F. Kern<sup>2</sup>

<sup>1</sup>JPT Peptide Technologies GmbH, Volmerstrasse 5 12489 Berlin, Germany, <sup>2</sup>Brighton and Sussex Medical School, Medical School Research Building, Rm 109, Brighton BN1 9PS, East Sussex, UK

The development of successful vaccines and other immunotherapies requires efficient immune monitoring techniques. Typically, antigen-specific T cell assays detect secreted cytokines (ELISA and ELISPOT) or intracellular cytokines (flow- cytometry). Pools of commonly recognized viral peptides are often used as positive controls in these assays, because they tend to induce responses in a majority of individuals. However, a considerable number of individuals respond only weakly or not at all to these pools, because they have not been exposed to the infectious agents covered, or, they do not have the required HLA-type to present one or more of the selected peptides. In some situations, individuals may not respond to such peptides despite previous exposure and the matching HLA-type, which is probably related to their specific T-cell receptor repertoire and epitope dominance hierarchies (1,2). In order to address this problem, we have developed an improved positive control pool that covers a wider range of target species and provides broader coverage of populations with different ethnic backgrounds than any other available peptide pool to date.

### Introduction

T-cell stimulation-dependent T-cell assays require positive controls to confirm that the tested cells were able to respond to an adequate stimulus in principle. One frequently used positive control is a panel of 23 MHC class I presented viral peptides called 'CEF pool' (3). This pool consists of known epitopes from Cytomegalovirus (CMV, HHV-5), Epstein-Barr virus (EBV, HHV-4), and Influenza A virus (Flu). The prevalence of infection with each of these viruses in adults exceeds 50-80%, depending on the virus and the studied population. As a result, there is a high degree of probability that most individuals will have T-cells specific for at least one of these viruses. Modified versions of the CEF pool contain the original 23 peptides plus 9 additional peptides from the same viruses, referred to as 'Extended CEF pool' (32 peptides) or the original 23 peptides plus 4 additional stimulating peptides from *Clostridium tetani*, referred to as 'CEFT pool' (27 peptides). These extended versions are widely accepted and now more frequently used than the original CEF pool. However, the huge diversity of MHC in humans, the human leukocyte antigen (HLA for short), adds another layer of complexity. The original CEF pool was designed to cover the most frequent HLA alleles found in European-Caucasoids. However, in other ethnic groups different HLA-alleles/allele groups dominate. Therefore, the existing positive control pools often do not work as well in other ethnic groups as they do in European-Caucasoids. Here we describe the design of a novel, enhanced positive control-pool with a strongly improved coverage of infectious agents and HLA-alleles.

### Methods

The abundance of known stimulating peptides and their presenting HLA-alleles prompted the extension of existing positive control pools in terms of the number of infectious agents targeted and HLA-types covered in order to increase the probability of a positive T-cell response. Together, the 50 peptides already used in various JPT control pools (CEF, CEF (extended), CEFT, and CEFT MHC-II) formed the core pool to be extended. As a first step, we searched publications and publicly available epitope repositories for relevant epitopes covering a wide range or relevant organisms and HLA-types (4). This search yielded several hundred stimulating peptides of interest. The subsequent peptide selection was carried out with the aim of covering a majority of ethnic backgrounds. Information published by the US National Bone Marrow Donor

Program on the HLA allele frequencies of 5.7 million individuals divided into 16 ethnic groups (5) was used to calculate, for each peptide, the percentage of the population that would theoretically be able to respond to this peptide based on the presence of the presenting HLA-allele or allele group (population coverage).


**Table 1: Organism coverage of CEFX and EFX Pools**

Coxsackievirus B4, Human adenovirus 5, Human herpesvirus 1, Human herpesvirus 2, Human herpesvirus 3, Human herpesvirus 4, Human herpesvirus 6, Human papillomavirus, JC polyomavirus, Measles virus, Rubella virus, Vaccinia virus, Clostridium tetani, Influenza A virus, Helicobacter pylori, and Toxoplasma gondii  
Human herpesvirus 5 (HCMV) not contained in EFX

As a baseline, the population coverage for the existing core pool was calculated. Subsequently, the coverage gained with each candidate peptide to be added was calculated and the peptide was included in the final pool if the increase in coverage was >5% (across all ethnic groups). Peptides predicted to be chemically unstable were excluded. The final pool encompassed 176 peptides derived from 17 organisms (Table 1). Apart from serving as a positive assay control, it might be of interest to compare the responses induced by such a comprehensive positive control pool between different individuals (or groups of individuals) to assess T-cell immunity in a more general way. For this purpose, we have designed two new pools, one including and one excluding peptides from Human herpesvirus 5 (CMV). The pools are referred to as **CEFX Ultra SuperStim Pool** (including CMV peptides) or **EFX Ultra SuperStim Pool** (excluding CMV peptides). CMV often leads to very large T-cell responses that could make a fair comparison between CMV-infected and uninfected individuals difficult if the CEFX Ultra SuperStim Pool were used. Please see Table 1 for the species coverage of the new pools. The gain in population MHC coverage of the CEFX/EFX pools compared to the currently most widely used pool, the CEFT pool, is shown in Figure 1.

### Results

PBMC were used in an IFN- $\gamma$  ELISPOT assay and stimulated with the standard positive control pools, CEFT, and the new pools, CEFX and EFX Ultra SuperStim Pools. A significantly higher number of spots was observed with CEFX and EFX Ultra SuperStim Pools compared to CEFT, translating into a 50% response increase in the example in Fig. 2. In order to obtain



representative estimates for the expected (average) response increase, a larger series of tests is currently being carried out.

**Discussion & Conclusions**

Two new control pools, CEFX and EFX Ultra SuperStim Pools, were created based on a library of known epitopes from multiple species with a high level of endemic infection. The selection was based on observed or predicted HLA allele associations as well as reported HLA allele frequencies for a wide range of ethnic backgrounds. Theoretical organism coverage and population HLA coverage of the new positive control pools are superior to those of the most popular, conventional positive control pools in current use, for example the CEFT pool. Our new CEFX and EFX Ultra SuperStim Pools, therefore, have a much higher probability of causing a positive response in a given individual than conventional pools and should, therefore, be preferred in most situations.

2. A new perspective of the Structural complexity of HCMV-specific T-cell responses. Sylwester et al., Mech Ageing Dev (2016).
3. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. Currier et al., J Immunol Methods (2002).
4. The immune epitope database (IEDB) 3.0. Vita et al., Nucleic Acids Res (2014)
5. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Gragert L et al., Hum Immunol. (2013).

**The Authors**

**Dr. Maren Eckey**

eckey@jpt.com

Group Leader Research & Development JPT Peptide Technologies  
Dr. Maren Eckey obtained her PhD at the Justus-Liebig University in Giessen. She was a postdoc at the Ludwig-Maximilian University in Munich before she joined JPT.

**Dr. Ulf Reimer**

reimer@jpt.com

Head of Research & Development JPT Peptide Technologies GmbH  
Dr. Ulf Reimer studied Biochemistry at Martin-Luther University Halle/Wittenberg and completed his PhD at the Max-Planck-Society at Halle/Saale. He joined JPT in 2010.

**Prof. Florian Kern**

kern@jpt.com

Chair in Immunology Brighton and Sussex Medical School Brighton, East Sussex, UK

Prof. Florian Kern is Head of Immunology at JPT Peptide Technologies and Chair of Immunology at Brighton and Sussex Medical School, Brighton, United Kingdom.


**The Company**

JPT Peptide Technologies is a DIN ISO 9001:2015 certified integrated provider of innovative peptide solutions for: cellular and humoral immune monitoring, seromarker discovery & validation, vaccine target discovery, peptide lead identification & optimization, targeted proteomics, and enzyme profiling.

**Contact us:** [peptide@jpt.com](mailto:peptide@jpt.com)

**Visit us:** [www.jpt.com](http://www.jpt.com)

**Further reading:** [Control Pools](#)



**References**

1. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. Betts et al., J Virol (2000)